Antibodies News and Research

RSS
Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

Intranasal interferon-λ treatment protects mice against SARS-CoV-2 Beta and Omicron variants

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

Diagnosing COVID-19 with the new isothermal amplification technology

Diagnosing COVID-19 with the new isothermal amplification technology

Novel molecular signaling pathway plays a key role in producing osteoarthritis pain

Novel molecular signaling pathway plays a key role in producing osteoarthritis pain

Structural proteomics approaches can help in the treatment of neurodegenerative diseases

Structural proteomics approaches can help in the treatment of neurodegenerative diseases

SARS-CoV-2 virus may be shed for much longer periods by some infected patients, study shows

SARS-CoV-2 virus may be shed for much longer periods by some infected patients, study shows

Early-stage alveolar epithelial cell necrosis linked to COVID-19-induced acute respiratory distress syndrome

Early-stage alveolar epithelial cell necrosis linked to COVID-19-induced acute respiratory distress syndrome

Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants

Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Risk of long COVID-19 predicted by immunoglobulin signature

Risk of long COVID-19 predicted by immunoglobulin signature

Targeting SARS-CoV-2 M protein may help ease severity of COVID-19

Targeting SARS-CoV-2 M protein may help ease severity of COVID-19

COVID-19 vaccination does not affect fertility outcomes in patients undergoing in-vitro fertilization

COVID-19 vaccination does not affect fertility outcomes in patients undergoing in-vitro fertilization

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

Omicron RBD mutations increase ACE2 binding and reduce antibody sensitivity

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

Immunosuppressed patients can benefit from COVID-19 booster vaccination, study shows

Immunosuppressed patients can benefit from COVID-19 booster vaccination, study shows

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

New research on SARS-CoV-2 Omicron and care home residents

New research on SARS-CoV-2 Omicron and care home residents

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.